drugset / Trial / NCT02756130
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Phase 1/2
Withdrawn
Jonsson Comprehensive Cancer Center
Alpha Stem Cell Clinic (ASCC) · collabCalifornia Institute for Regenerative Medicine (CIRM) · collabTetraLogic Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as birinapant and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2020-02-01
- Completion
- 2021-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Birinapant | Small molecule | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |